TREATMENT
Review: home-made and commercial spacers did not differ for delivery of inhaled β2 agonists in children with asthma or wheezing
| The first 150 words of the full text of this article appear below. |
C Rodriguez-Martinez
Dr C Rodriguez-Martinez, Clínica Colsánitas, Bogota, Colombia; carlos_rodriguez2671@yahoo.com
In children with acute asthma or lower airway obstruction attacks, how do home-made and commercial spacers attached to metered-dose inhalers (MDIs) compare for delivering β2 agonists?
Studies selected compared rapid-acting β2 agonists delivered by MDIs attached to home-made spacers with MDIs attached to commercial spacers in children and adolescents <18 years of age presenting to the emergency department (ED) with acute exacerbations of wheezing or asthma. Outcomes included hospital admission, lung function (peak expiratory flow rate [PEFR], oxygen saturation, and respiratory rate), heart rate, clinical score, intensive care unit (ICU) admission, length of ED stay, and need for additional treatment.
Medline, CINAHL, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, Cochrane Library (Issue 3, 2007), LILACS, and reference lists were searched. Authors and pharmaceutical companies were contacted for randomised controlled trials (RCTs). 6 RCTs (n = 658, age range 2
Laurentian University, Sudbury, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
